...
首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Plasma haemostatic potential of haemodialysis patients assessed by thrombin generation assay: Hypercoagulability in patients with vascular access thrombosis
【24h】

Plasma haemostatic potential of haemodialysis patients assessed by thrombin generation assay: Hypercoagulability in patients with vascular access thrombosis

机译:凝血酶生成测定法评估血液透析患者的血浆止血潜力:血管通路血栓形成患者的高凝性

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction Patients with end-stage renal disease (ESRD) on maintenance haemodialysis are predisposed to bleeding and thrombotic events. Recently thrombin generation assay (TGA) has been introduced as a laboratory assessment of global haemostatic potential. We investigated the global haemostatic potential assessed by TGA in ESRD patients on haemodialysis and patients who developed vascular access thrombosis. Materials and Methods A total of 69 ESRD patients who underwent haemodialysis (58 stable patients and 11 vascular access thrombosis patients) were included and 33 healthy controls were included. TGA was performed on the calibrated automated thrombogram using tissue factor with/without addition of thrombomodulin or activated protein C, producing three parameters including lag time, endogenous thrombin potential (ETP) and peak thrombin. Results Haemodialysis patients showed low ETP values measured by thrombin generation assay compared with the healthy controls. Interestingly, patients with vascular access thrombosis exhibited short PT and aPTT and increased resistance of coagulation inhibition to APC anticoagulant protein, reflecting hyper-coagulability. Haemodialysis patients who are taking anti-platelet agents showed decreased thrombin inhibition rate, representing antithrombotic effect of anti-platelet agents. Conclusion Whereas the haemodialysis patients showed hypo-coagulability, the patients with vascular access thrombosis exhibited hyper-coagulability. Further study is required to investigate how this haemostatic potential may be utilized to guide the physician to more effective management of haemostatic complication.
机译:简介维持性血液透析的终末期肾脏病(ESRD)患者易发生出血和血栓形成事件。最近,已引入凝血酶生成测定(TGA)作为全球止血潜力的实验室评估。我们调查了由TGA评估的ESRD血液透析患者和发生血管通路血栓形成的患者的总体止血潜力。材料和方法总共纳入了69名接受血液透析的ESRD患者(58名稳定患者和11名血管通路血栓形成患者),并包括33名健康对照。使用或不添加血栓调节蛋白或活化蛋白C的组织因子对校准的自动血栓图进行TGA,产生三个参数,包括滞后时间,内源性凝血酶电势(ETP)和峰值凝血酶。结果与健康对照相比,血液透析患者显示通过凝血酶生成测定法测得的ETP值较低。有趣的是,具有血管通路血栓形成的患者表现出短的PT和aPTT以及对APC抗凝蛋白的凝结抑制能力增加,反映出高凝结性。服用抗血小板药的血液透析患者显示凝血酶抑制率降低,代表抗血小板药的抗血栓作用。结论血液透析患者表现出低凝结性,而血管通路血栓形成者表现出高凝结性。需要进一步的研究来研究如何利用这种止血潜力来指导医生更有效地治疗止血并发症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号